308 related articles for article (PubMed ID: 8185638)
21. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
22. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.
Kobayashi K; Chiba K; Yagi T; Shimada N; Taniguchi T; Horie T; Tani M; Yamamoto T; Ishizaki T; Kuroiwa Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):927-33. PubMed ID: 9023308
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 isozymes involved in aromatic hydroxylation and side-chain N-desisopropylation of alprenolol in rat liver microsomes.
Narimatsu S; Tachibana M; Masubuchi Y; Imaoka S; Funae Y; Suzuki T
Biol Pharm Bull; 1995 Aug; 18(8):1060-5. PubMed ID: 8535396
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 isoforms responsible for the N-deethylation and cyclohexane-hydroxylation of NS-21.
Nakamura A; Hirota T; Morino A; Imaoka S; Funae Y; Yamamoto Y; Tasaki T; Masuda M; Kazusaka A; Fujita S
Xenobiotica; 1999 Mar; 29(3):243-52. PubMed ID: 10219965
[TBL] [Abstract][Full Text] [Related]
25. A new radioligand binding assay for cytochrome P450IID1 (CYP2D1) in rat liver microsomes: a tool to predict sparteine/debrisoquine type polymorphism of drugs.
Voss HP; Leurs R; Donnell D; Bast A
J Pharmacol Toxicol Methods; 1994 Jun; 31(3):149-52. PubMed ID: 8068976
[TBL] [Abstract][Full Text] [Related]
26. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism.
Liu Z; Mortimer O; Smith CA; Wolf CR; Rane A
Br J Clin Pharmacol; 1995 Jan; 39(1):77-80. PubMed ID: 7756104
[TBL] [Abstract][Full Text] [Related]
27. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.
Larrey D; Distlerath LM; Dannan GA; Wilkinson GR; Guengerich FP
Biochemistry; 1984 Jun; 23(12):2787-95. PubMed ID: 6432035
[TBL] [Abstract][Full Text] [Related]
28. Regioselectivity and substrate concentration-dependency of involvement of the CYP2D subfamily in oxidative metabolism of amitriptyline and nortriptyline in rat liver microsomes.
Masubuchi Y; Iwasa T; Fujita S; Suzuki T; Horie T; Narimatsu S
J Pharm Pharmacol; 1996 Sep; 48(9):925-9. PubMed ID: 9036183
[TBL] [Abstract][Full Text] [Related]
29. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2.
Yamamoto Y; Tasaki T; Nakamura A; Iwata H; Kazusaka A; Gonzalez FJ; Fujita S
Pharmacogenetics; 1998 Feb; 8(1):73-82. PubMed ID: 9511184
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC; Nation RL; Somogyi AA
Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
[TBL] [Abstract][Full Text] [Related]
33. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the oxidation reactions catalyzed by CYP2D enzyme in rat renal microsomes.
Masubuchi Y; Yamamoto K; Suzuki T; Horie T; Narimatsu S
Life Sci; 1996 May; 58(26):2431-7. PubMed ID: 8691988
[TBL] [Abstract][Full Text] [Related]
35. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation.
Yasumori T; Li QH; Yamazoe Y; Ueda M; Tsuzuki T; Kato R
Pharmacogenetics; 1994 Dec; 4(6):323-31. PubMed ID: 7704038
[TBL] [Abstract][Full Text] [Related]
36. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
Laurenzana EM; Sorrels SL; Owens SM
Drug Metab Dispos; 1995 Feb; 23(2):271-8. PubMed ID: 7736924
[TBL] [Abstract][Full Text] [Related]
37. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
Eagling VA; Tjia JF; Back DJ
Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol.
Rowland K; Yeo WW; Ellis SW; Chadwick IG; Haq I; Lennard MS; Jackson PR; Ramsay LE; Tucker GT
Br J Clin Pharmacol; 1994 Jul; 38(1):9-14. PubMed ID: 7946944
[TBL] [Abstract][Full Text] [Related]
39. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
40. Evidence for CYP2D1-mediated primary and secondary O-dealkylation of ethylmorphine and codeine in rat liver microsomes.
Xu BQ; Aasmundstad TA; Christophersen AS; Mørland J; Bjørneboe A
Biochem Pharmacol; 1997 Feb; 53(4):603-9. PubMed ID: 9105413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
